Headlines

Chemomab Therapeutics’ Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab’s OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.

read more

Join the newsletter

Subscribe to get our latest content by email.

    We respect your privacy. Unsubscribe at any time.

    Leave a Reply

    Your email address will not be published. Required fields are marked *